Abstract
Introduction: Serum level of high sensitivity C-reactive protein (hs-CRP), as an inflammatory marker, can play a role in development of metabolic syndrome in obese individuals. Objectives: This study aimed to determine serum concentration of hs-CRP in obese patients with metabolic syndrome and determine the association of this factor with factors involved in the progression of metabolic syndrome. Patients and Methods: In this study, samples were selected by convenient method from obese patients, admitted to Kashani and Hajar hospitals (Shahrekord, Iran). First, based on NCEP-ATPIIIdefined metabolic syndrome, parameters of metabolic syndrome and serum levels of vitamin D were measured and a questionnaire containing demographics was completed for each participant. Accordingly, the samples (n=192) were divided into two identical groups; obese individuals without metabolic syndrome (controls) and obese individuals with metabolic syndrome (case group). HsCRP levels were measured in both groups. Results: Serum level of hs-CRP in the case group was 17.58±1.40 µg/mL and in the control group was 9.04±1.26 µg/mL, which was significantly higher in the case group than the control group (P 0.05). Conclusion: Hs-CRP can be used for prognosis and early detection of patients at risk of metabolic syndrome.
Highlights
Serum level of high sensitivity C-reactive protein, as an inflammatory marker, can play a role in development of metabolic syndrome in obese individuals
Mean of serum level of high sensitivity C-reactive protein (hs-CRP) in the case group was 17.58 ± 1.40 μg/mL and in the control group was 9.04 ± 1.26 μg/mL, which was significantly higher in the case group than the control group (P < 0.001) with a maximum level of hs-CRP at 36.4 μg/mL and minimum at 0.1 μg/mL
Hs-CRP was significantly associated with weight in the control group (r=-0.31; P < 0.001), but there was no significant association in the case group (P > 0.05)
Summary
Serum level of high sensitivity C-reactive protein (hs-CRP), as an inflammatory marker, can play a role in development of metabolic syndrome in obese individuals. Metabolic syndrome is a serious complication that develops following a sedentary lifestyle and poor nutrition This syndrome was first introduced in 1998 as one of the background factors contributing to cardiovascular diseases and diabetes [1] and is known by other names, including syndrome X, insulin resistance syndrome, deadly quartet, obesity-dyslipidemia syndrome, and Reaven’s syndrome [2]. According to the recent researches, it involves up to 25% of the general population [3,4] This syndrome includes a number of clinical findings and laboratory abnormalities, such as obesity (central, abdominal or visceral), increased activity of the sympathetic nervous system, hypertension, glucose intolerance, insulin resistance, compensatory hyperinsulinemia, type 2 diabetes, dyslipidemia (hypertriglyceridemia, elevated low or high density lipoprotein cholesterol [HDL-C]), fatty liver, impaired fibrinolysis, hyperuricemia, systemic inflammation, especially endothelial dysfunction and vascular inflammation [5]. Identification of other causes of this syndrome can play an important role in awareness and early detection of this syndrome and its treatment control
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
